FDA advisory panel strongly backs biosimilar Remicade

(Reuters) - A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson's Remicade arthritis drug that could eventually batter sales of the branded product.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro